Skip to main content

Refractory dermatitis contributed by pityriasis versicolor: a case report

Abstract

Background

Dermatologic toxicity is a very common immune-related adverse event (irAE) for patients with melanoma who are receiving immune checkpoint inhibitor therapy (ICI). Concurrent skin infection, such as in the case of pityriasis versicolor reported here, can mimic and/or exacerbate dermatologic toxicity from irAE.

Case presentation

A 58-year-old Caucasian man with a history of pityriasis versicolor infection and metastatic melanoma received ICI therapy. He developed progressively worsening pruritic maculopapular lesions 22 weeks into his treatment that ultimately covered 40% of his body. He was diagnosed with dermatologic toxicity due to ICI therapy with concurrent pityriasis versicolor. He was initially started on topical steroid and topical antifungal cream but achieved minimum improvement. His treatment was then escalated to oral prednisone, but it only achieved modest control of his dermatitis. All subsequent attempts to wean him from oral prednisone resulted in worsening of his dermatitis. Eventually he was started on oral fluconazole in combination with prednisone, which led to rapid resolution of his dermatitis.

Conclusion

We report a case of dermatological toxicity due to an irAE with concurrent pityriasis versicolor. The steroid treatment for irAE was likely exacerbating the underlying fungal infection, and the fungal infection was in term mimicking the symptoms of irAE. This patient’s severe dermatitis was only brought under control after receiving a more potent antifungal therapy in combination with a steroid. It is vital to look beyond the irAE when managing dermatitis in patients receiving ICI therapy.

Peer Review reports

Background

Immune checkpoint inhibitors (ICI) have led to a remarkable improvement in the long-term survival of patients with melanoma and other types of cancer [1, 2]. However, the prevalence of ICI usage has led to a surge in a number of dermatologic toxicities due to immune-related adverse events (irAEs) [3]. For some patients, these irAEs have caused a considerable amount of morbidity and mortality [3]. Aside from frequent dermatologic toxicities, patients with irAEs frequently require treatment with immunosuppressive agents that can increase their risk for opportunistic skin infections [4]. Here we report a case of refractory dermatitis due to an irAE with associated underlying pityriasis versicolor.

Case presentation

A 58-year-old Caucasian man with a history of pityriasis versicolor and metastatic melanoma was started on pembrolizumab 200 mg every 21 days. He developed pruritic maculopapular rashes throughout his body 22 weeks into the treatment course. In some areas, the maculopapular lesions coalesced into patches and plaques. Many of these lesions were scaly in appearance and resembled his prior pityriasis versicolor infection. The skin eruptions were mainly in the abdomen, back, and extremities (Figs. 1, 2). He was started on topical betamethasone diproprionate 0.05% and miconazole nitrate 2% cream for the dermatitis due to the irAE with associated underlying pityriasis versicolor. The skin lesions improved with these topical therapies.

Fig. 1
figure1

Time-line showing the severity of the dermatitis (top, red bars) over time, and treatment with prednisone in milligrams (bottom, black bars) and other treatments (green bars).

Fig. 2
figure2

Initial presentation of dermatitis involving the back(a), lower extremity (b), hands (c), and right lateral torso (d)

By 25 weeks after starting pembrolizumab, his melanoma then progressed and the immunotherapy regimen was switched to ipilimumab 3 mg/kg every 21 days. Five weeks later, he had a worsening of the dermatitis with severe pruritus. The dermatitis covered approximately 40% of his body surface area and involved his torso, bilateral hands, and lower extremities (Fig. 3). A second course of topical betamethasone diproprionate 0.05% cream, daily cetirizine 10 mg tablet, and miconazole nitrate 2% cream was administered to the patient, without improvement. Oral prednisone 50 mg (0.5 mg/kg) daily was then prescribed, and the extent of his rashes from dermatitis improved.

Fig. 3
figure3

Worsening of dermatitis after his initial presentation in the lower extremities (a) and torso (b)

Subsequent multiple attempts to wean him from the prednisone resulted in rapid worsening of his skin condition. His melanoma disease burden continued to worsen and ipilimumab was discontinued, although the dermatitis did not abate. His diffuse rashes were only moderately controlled with prednisone and topical antifungal cream. Due to the persistent refractory dermatitis, which resembled his prior pityriasis versicolor eruptions, the decision was taken to treat the dermatitis with a stronger oral antifungal therapy for pityriasis versicolor while continuing prednisone for the dermatologic toxicity due to the irAE. He was started on fluconazole 200 mg daily on day 1 followed by 100 mg daily for 6 additional days while continuing with a prednisone taper at 15 mg daily. A skin biopsy of the flank torso was also performed on the day of starting fluconazole and showed superficial middle dermal perivascular dermatitis with associated spongiosis. The pathology was compatible with hypersensitivity from either medication or other potential allergens. The rashes resolved within days after starting fluconazole without any reported intolerability to the treatment, and the patient came off the prednisone shortly without the need of any further escalation.

His performance status remained optimal, and his treatment was switched to temozolomide 5 weeks later given optimal performance status. Unfortunately his cancer progressed further, and he was rechallenged with nivolumab 1 year later. No significant dermatological toxicity was noted.

Discussion

As the indications for ICI are expanding at a rapid pace, we are seeing an increasing number of patients with moderate to severe irAEs. Approximately 30–40% of patients who are treated with programmed cell death protein 1 (PD-1) blockers, such as nivolumab or pembrolizumab, develop dermatologic complications [3, 5]. More severe dermatological incidents are seen in patients treated with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, such as ipilimumab, and significantly worse irAEs are often seen with the combination of PD-1/CTLA-4 inhibitors [3].

Many oncologists have adapted the grading system of the Common Terminology Criteria for Adverse Events Version 5 (CTCAE v5) to quantify the severity of irAEs, and a myriad of organizations have designed protocols in an attempt to streamline the diagnosis and treatment of dermatologic irAEs [6, 7]. Current guidelines recommend a thorough diagnostic workup to rule out other potential etiologies, such as infections, reactions from another medications, and systemic diseases [7]. A consultation with an experienced dermatologist familiar in managing dermatologic irAEs is highly recommended for CTCAE grade 3 or higher skin toxicity before resuming ICI [6, 7].

In addition to the dermatologic toxicity due to the irAE, this patient had an underlying pityriasis versicolor. Pityriasis versicolor is a very common fungal infection in tropical climates and a less frequently occurring one in other climate zones. It is caused by Malassezia species, which is a skin flora saprophyte [8]. The exact mechanism of pathogenesis is unknown, but the immunosuppressed patients have an increased risk of developing pityriasis versicolor [4]. The skin lesions can appear in multiple forms, ranging from mildly erythematous to hypopigmented forms, and sometimes hyperpigmented ones. In the advanced form, these small lesions can become confluent [8]. Most patients with pityriasis versicolor are asymptomatic and only experience cosmetic changes of their skin [8]. However, in patients who are receiving oral corticosteroid or who are immunocompromised, these infections can be severe [8]. Patients with pityriasis versicolor are usually diagnosed by physical examation. Light microscopy observation of a potassium hydroxide preparation can be used for confirmation [8]. Skin infection due to pityriasis versicolor generally responds well to topical antifungal agents [9]. The typical duration of treatment ranges from 1 to 4 weeks [9]. Oral antifungal agents, such ketoconazole, itraconazole, or fluconazole, are reserved for florid infection or recurrent disease [9].

Our patient had dermatitis due to an irAE from pembrolizumab and ipilimumab. In addition, he had pityriasis versicolor that predated the immunotherapy and which was exacerbated by the treatment for the irAE. His underlying fungal infection was mimicking features of the dermatologic toxicity due to the irAE. Although the pityriasis versicolor was diagnosed based on the clinical features and no yeast or hyphae were seen on biopsy, the rapid resolution of his dermatitis after a short course of intensified antifungal therapy indirectly confirmed our diagnosis. We suspected that the chronic topical antifungal and steroid cream might have contributed to a false negative biopsy result. Given that his rash was already resolved, we did not perform any additional fungal testing. Furthermore, no significant skin toxicity was noted when he was rechallenged with nivolumab.

In this case, it is possible that fluconazole, a CYP3A4 inhibitor, could potentially have increased the serum concentration of prednisone due to drug–drug interactions [10]. However, our patient was only receiving a very low dose of prednisone when the treatment with the low dose of fluconazole was started. The complete resolution of his skin condition could not be adequately explained by a small to moderate increase in steroid concentration alone. In addition, he did not require any additional escalation of steroid dose after completing the 7-day course of fluconazole. His overall response to treatment was consistent with the dermatologic toxicity due to an irAE with an associated underlying fungal infection.

Conclusion

Immunotherapy is standard of care for many cancers. Although treated patients frequently develop dermatitis as a part of irAEs, one must remain vigilant and consider other potential differential diagnoses other than irAEs when managing ICI-related dermatologic complications.

Availability of data and materials

In accordance with local and/or U.S. Government laws and regulations, any materials and de-identified data that are reasonably requested by others will be made available in a timely fashion.

Abbreviations

CTLA-4:

Cytotoxic T-lymphocyte-associated protein 4

ICI:

Immune checkpoint inhibitors

irAEs:

Immune-related adverse events

PD-1:

Programmed cell death protein 1

References

  1. 1.

    Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582–8.

    CAS  Article  Google Scholar 

  2. 2.

    Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol. 2019.

  3. 3.

    Sibaud V. Dermatologic reactions to immune checkpoint inhibitors : skin toxicities and immunotherapy. Am J Clin Dermatol. 2018;19(3):345–61.

    Article  Google Scholar 

  4. 4.

    Gulec AT, Demirbilek M, Seckin D, Can F, Saray Y, Sarifakioglu E, et al. Superficial fungal infections in 102 renal transplant recipients: a case-control study. J Am Acad Dermatol. 2003;49(2):187–92.

    Article  Google Scholar 

  5. 5.

    Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26(12):2375–91.

    CAS  Article  Google Scholar 

  6. 6.

    U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0. 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf.

  7. 7.

    Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714–68.

    CAS  Article  Google Scholar 

  8. 8.

    Gupta AK, Bluhm R, Summerbell R. Pityriasis versicolor. J Eur Acad Dermatol Venereol. 2002;16(1):19–33.

    CAS  Article  Google Scholar 

  9. 9.

    Hu SW, Bigby M. Pityriasis versicolor: a systematic review of interventions. Arch Dermatol. 2010;146(10):1132–40.

    Article  Google Scholar 

  10. 10.

    Van Matre ET, Satyanarayana G, Page RL 2nd, Levi ME, Lindenfeld J, Mueller SW. Pharmacokinetic drug-drug interactions between immunosuppressant and anti-infective agents: antimetabolites and corticosteroids. Ann Transplant. 2018;23:66–74.

    Article  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

The funding for the publication of this case report is supported by the division of hospital medicine at the Ohio State University Wexner Medical Center.

Author information

Affiliations

Authors

Contributions

All authors have made substantial contributions to the conception of this case report, acquisition and interpretation of the data, drafting and revisions of the manuscript, and the final approval manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Mingjia Li.

Ethics declarations

Ethics approval and consent to participate

Not applicable

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

The authors have no financial or nonfinancial competing interests to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Li, M., Spaccarelli, N., Kendra, K. et al. Refractory dermatitis contributed by pityriasis versicolor: a case report. J Med Case Reports 15, 212 (2021). https://doi.org/10.1186/s13256-021-02818-1

Download citation

Keywords

  • Immune-related adverse event
  • Skin infection
  • Dermatitis
  • Pityriasis versicolor
\